Novartis AG (SWX:NOVN) agreed to acquire Calypso Biotech B.V. for $425 million on January 8, 2024. Calypso?s shareholders will receive an upfront payment of $250 million upon closing and are eligible to receive development milestones of up to $175 million. Lazard B.V. acted as financial advisor and Goodwin Procter LLP acted as legal advisor to Calypso Biotech B.V.